Cerebral Metastases in Breast Cancer Patients Treated with Trastuzumab
Author Information
Author(s): Clayton A J, Danson S, Jolly S, Ryder W D J, Burt P A, Stewart A L, Wilkinson P M, Welch R S, Magee B, Wilson G, Howell A, Wardley A M
Primary Institution: Christie Hospital NHS Trust
Hypothesis
The prolongation of survival of patients with metastatic breast cancer using therapies which do not penetrate the CNS will result in a higher incidence of clinically overt cerebral metastases than has hitherto been observed.
Conclusion
A high proportion of patients treated with trastuzumab for metastatic breast cancer develop symptomatic brain metastases.
Supporting Evidence
- 25% of patients developed symptomatic brain metastases after starting trastuzumab therapy.
- 39% of patients who died had brain metastases diagnosed before death.
- Patients with ER-negative breast cancer were more likely to develop brain metastases.
Takeaway
This study found that many breast cancer patients treated with a drug called trastuzumab ended up with brain tumors, which is surprising because the drug doesn't reach the brain well.
Methodology
A retrospective review of case notes was conducted to identify patients treated with trastuzumab and to analyze the development of cerebral metastases.
Potential Biases
Potential bias may arise from the single-institution study design and the retrospective analysis.
Limitations
The study is limited by its retrospective nature and the exclusion of patients with inadequate follow-up documentation.
Participant Demographics
The study included 93 patients with a median age of 48 years, with a majority being HER-2 positive.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 13.5–36.9%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website